miRNA (microRNA) and FGF21 (Fibroblast Growth Factor-21) Profile in First Trimester and Gestational Diabetes Prediction
NCT ID: NCT05632055
Last Updated: 2022-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
160 participants
OBSERVATIONAL
2000-08-26
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be retrieved blood sample during first trimester and undergone 100 gm OGTT (oral glucose challenge test) during 24-28 weeks of gestation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fibroblast Growth Factors 19 and 21 in Gestational Diabetes Mellitus
NCT01858597
Stratification of Risk of Diabetes in Early Pregnancy
NCT03005600
Genetic and Epigenetic Mechanisms of Developing Gestational Diabetes Mellitus and Its Effects on the Fetus
NCT03610178
Risk Factors and Diagnostic Performance of Predictors as a Screening Technique for Gestational Diabetes Mellitus
NCT06109597
The Early Diagnosis of Gestational Diabetes Mellitus Study
NCT02740283
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants received routine standard prenatal care except,
1. additional blood test during 11-13 week 6 days (Blood was collected for further analysis)
2. performed 75gm OGTT during 24-28 week
Baseline data and pregnancy outcome were reviewed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregnancy with GDM
Pregnant women who positive test for 100gm OGTT (abnormal 2 or more blood glucose level according NDDG (National Diabetes Data Group) criteria)
blood draw
Blood test for miRNA and FGF21. However, the laboratory result is not reported and not involved in management
Pregnancy without GDM
Pregnant women who negative test for 100gm OGTT
blood draw
Blood test for miRNA and FGF21. However, the laboratory result is not reported and not involved in management
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood draw
Blood test for miRNA and FGF21. However, the laboratory result is not reported and not involved in management
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* normal structural fetal anatomical screening
* incomplete obstetric data
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chiang Mai University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kuntharee Traisrisilp
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maharaj Nakorn ChiangMai Hospital
Chiang Mai, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OBG-2563-07494
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.